Allergan Can't Escape Botox Antitrust Suit
A California federal judge on Tuesday refused to toss a surgical center's proposed class action accusing Allergan of licensing a Korean-made drug arguably superior to its Botox treatment in order to...To view the full article, register now.
Already a subscriber? Click here to view full article